<DOC>
	<DOCNO>NCT02623595</DOCNO>
	<brief_summary>The purpose study determine whether stereotactic body radiotherapy ( SBRT ) combine recombined human granulocyte-macrophage colony stimulate factor ( rhGM-CSF ) safe , effective treatment stage IV NSCLC patient fail second-line chemotherapy .</brief_summary>
	<brief_title>A Study SBRT Combination With rhGM-CSF Stage IV NSCLC Patients Who Failed Second-line Chemotherapy</brief_title>
	<detailed_description>Metastasis lesion treat SBRT 50Gy/5F day 1 day 5 one cycle.Subcutaneous injection human recombine granulocyte-macrophage colony stimulate factor ( 125ug/m² per day ) execute day 1 day 14 cycle . Another metastasis lesion treat likewise concurrently rhGM-CSF consecutive cycle . Efficacy evaluation , especially abscopal effect evaluation , conduct end therapy every month . Adverse event record accord NCI-CTC version 4.03 .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Histologically proven nonsmallcell lung cancer . 2 . Stage IV accord UICC stage system ( version 7,2009 ) . 3 . Progression standard secondline chemotherapy . 4 . At least Three evaluable lesion among least two must suitable SBRT . 5 . ECOG performance status 02 . 6 . Expected lifespan ≥3 month . 7 . Stable lab value : Hematological : Absolute neutrophil count ( ANC ) ≥1.5×109/L , Platelets ≥100×109/L , Hemoglobin ≥9 g/dL Renal : Creatinine OR Measured calculate creatinine clearance ( CrCl ) ( glomerular filtration rate [ GFR ] also use place creatinine CrCl ) ≤1.5× upper limit normal ( ULN ) OR ≥60 mL/min patient creatinine level &gt; 1.5× institutional ULN Hepatic : Total bilirubin ≤1.5×ULN OR Direct bilirubin ≤ULN patient total bilirubin level &gt; 1.5×ULN , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5×ULN OR ≤5×ULN patient liver metastasis , globulin≥20 g/L , albumin≥30 g/L . 8 . Female subject must negative urine serum pregnancy test within 72 hour prior take study drug childbearing potential . 9 . Able understand give write informed consent comply study procedure . Exclusion criterion : 1 . Any unstable systemic disease , include active infection , uncontrolled high blood pressure , unstable angina , newly observe angina pectoris within past 3 month , congestive heart failure ( New York heart association ( NYHA ) class II high ) , myocardial infarction onset six month include group , severe arrhythmia , liver , kidney , metabolic disease need drug therapy . 2 . Any clinical evidence suggest moderately severe chronic obstructive pulmonary disease ( COPD ) [ With COPD history relate risk factor , FEV1 / FVC &lt; 70 % , FEV1 &lt; 80 % estimate value , without chronic cough , sputum , dyspnea symptom ) , active interstitial lung disease ILD ( FEV1 / FVC &lt; 70 % , FEV1 &lt; 80 % estimate value , carbon monoxide diffusion capacity lung DLCO &lt; 40 % , high resolution CT ( HRCT ) confirm diffuse pulmonary interstitial lesion ] active pulmonary disease . 3 . Previously diagnose autoimmune disease , include limited systemic lupus erythematous , rheumatoid arthritis , systemic vasculitis , scleroderma , dermatomyositis , autoimmune hemolytic anemia autoimmune liver disease , autoimmune thyroiditis . 4 . Human immunodeficiency virus ( HIV ) infection . 5 . Women pregnancy lactation . 6 . Medicine abuser ( include alcohol , drug addictive drug abuser ) . 7 . Patients mental illness , consider `` ca n't fully understand issue research '' . 8 . Cancer history within 5 year apart NSCLC enrollment . 9 . Histologically confirm small cell carcinoma non NSCLC composition cancer tissue . 10 . Cancer treatment within 4 week , include limited palliative surgery , radiotherapy , chemotherapy target therapy . 11 . Tumor related immunotherapy within 1 year , include limited immune cell therapy , tumor vaccine therapy , immune checkpoint monoclonal antibody related treatment , cytokine treatment except GMCSF . 12 . Allergy rhGMCSF accessory . 13 . Contraindications GMCSF treatment . 14 . Patients unilateral lung .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>Stereotactic body radiotherapy</keyword>
	<keyword>abscopal effect</keyword>
	<keyword>safety</keyword>
	<keyword>immunotherapy</keyword>
</DOC>